Galectin-3- Mediated Transdifferentiation of Pulmonary Artery Endothelial Cells Contributes to Hypoxic Pulmonary Vascular Remodeling

Cell Physiol Biochem. 2018;51(2):763-777. doi: 10.1159/000495331. Epub 2018 Nov 21.

Abstract

Background/aims: Vascular muscularity is a key event in vessel remodeling during pulmonary artery hypertension (PAH). Endothelial-mesenchymal transdifferentiation (EndMT) has been increasingly reported to play a role in disease occurrence. Galectin-3, a carbohydrate-binding protein regulates cell proliferation, differentiation, migration and neovascularization. However, whether galectin-3 controls endothelial cell transdifferentiation during the development of PAH is unknown.

Methods: Rats were exposed to normoxic or hypoxic conditions (fraction of inspired O2 0.10) for 21 d to establish PAH models. Hemodynamic changes were evaluated through surgery of the right jugular vein and ultrasound biomicroscopy inviVue. And vessel pathological alterations were detected by H&E staining. Galectin-3 (Gal-3)-induced pulmonary artery endothelium cell (PAEC) dynamic alterations were measured by MTT assays, Cell immunofluorescence, Flow cytometry, Real-time PCR and Western blot.

Results: Our study demonstrated that Gal-3 was expressed in hypoxic pulmonary vascular adventitia and intima. The increased Gal-3 expression was responsible for hypoxic vessel remodeling and PAH development in vivo. Gal-3 was found to inhibit cell proliferation and apoptosis in cultured endothelial cells. Meanwhile endothelial cell morphology was altered and exhibited smooth muscle-like cell features as demonstrated by the expression of α-SMA after Gal-3 treatment. Gal-3 activated Jagged1/Notch1 pathways and induced MyoD and SRF. When MyoD or SRF were silenced with siRNAs, Gal-3-initiated transdifferentiation in endothelial cells was blocked as indicated by a lack of α-SMA.

Conclusion: These results suggest that Gal-3 induces PAECs to acquire an α-SMA phenotype via a transdifferentiation process which depends on the activation of Jagged1/Notch1 pathways that mediate MyoD and SRF expression.

Keywords: Endothelial-mesenchymal transdifferentiation; vascular muscularity; Galectin-3; Pulmonary artery endothelial cells; Pulmonary artery hypertension.

MeSH terms

  • Animals
  • Cell Cycle Proteins / metabolism
  • Cell Survival / drug effects
  • Cell Transdifferentiation* / drug effects
  • Endothelial Cells / cytology
  • Endothelial Cells / metabolism
  • Galectin 3 / antagonists & inhibitors
  • Galectin 3 / genetics
  • Galectin 3 / metabolism*
  • Humans
  • Hypertension, Pulmonary / metabolism
  • Hypertension, Pulmonary / pathology
  • Lung / metabolism
  • Male
  • MyoD Protein / antagonists & inhibitors
  • MyoD Protein / genetics
  • MyoD Protein / metabolism
  • Pulmonary Artery / cytology
  • RNA Interference
  • RNA, Small Interfering / metabolism
  • Rats
  • Rats, Wistar
  • Receptor, Notch1 / metabolism
  • Recombinant Proteins / biosynthesis
  • Recombinant Proteins / pharmacology
  • Serum Response Factor / antagonists & inhibitors
  • Serum Response Factor / genetics
  • Serum Response Factor / metabolism
  • Vascular Remodeling* / drug effects

Substances

  • Cell Cycle Proteins
  • Galectin 3
  • MyoD Protein
  • Notch1 protein, mouse
  • RNA, Small Interfering
  • Receptor, Notch1
  • Recombinant Proteins
  • Serum Response Factor